CRVS Corvus Pharmaceuticals, Inc.
Price Chart
Executive Summary
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.
Actionable Insight
Focus shifts to SID meeting on May 14 for biomarker data that could support soquelitinib's differentiated profile. No near-term revenue catalysts. Monitor Phase 2 AD enrollment updates.
Key Facts
- Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
- Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
- Phase 2 atopic dermatitis trial initiated in Q1 2026
- Registrational Phase 3 PTCL trial enrollment continues
- New soquelitinib data to be presented at SID Annual Meeting May 13-16, 2026
Financial Impact
EPS $0.01 miss on $0.14 consensus is marginal; no revenue impact for pre-revenue biotech
Risk Factors
- Clinical trial failure or delays
- Dilution risk from future financing (cash runway to Q2 2028)
- No approved products or revenue
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003154 |
| Document: f8k_050726.htm | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index-headers.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154.txt | 0001171843-26-003154 |
| 8-K Data (Synthetic) | 0001171843-26-003154 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
8-K
| $13.66 $13.08 | ▼ −4.21% | ▼ −3.49% | $11.17 (−18.20%) |
|
May 7, 2026
4w ago
|
8-K
| $15.55 $13.66 | ▼ −12.19% | ▼ −13.65% | $11.17 (−28.17%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $15.92 $16.02 | ▲ +0.63% | ▲ +0.23% | $11.17 (−29.84%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $17.14 $15.62 | ▼ −8.87% | ▼ −9.95% | $11.17 (−34.83%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $15.32 $13.33 | ▼ −12.99% | ▼ −10.87% | $11.17 (−27.09%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $15.80 $15.32 | ▼ −3.01% | ▼ −1.48% | $11.17 (−29.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access